Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Replimune Group, Inc.

Past performance may not guarantee future results, but it can still provide valuable clues. When a stock suddenly breaks higher on unusually strong...

These 2 Stocks Just Broke Out — and They Could Go Higher, Say Analysts

As the second half of 2026 gets rolling, it’s a good time to step back and take a look at where we are. For starters, economic growth has remained ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REPL	$12.06	-6.22%	8.91M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REPL	$12.06	-6.2%	8.91M
3
4
5
6

REPL

REPL

Get Replimune Group, Inc. Data in Excel

Get Replimune Group, Inc. Data in Excel